5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
Allogene Therapeutics (NASDAQ:ALLO) Chief Financial Officer Parker Geoffrey M. sold 36,744 shares of common stock on October 21, 2025, at a price of $1.2565, totaling $46,168. The transaction comes as the stock trades near its 52-week low of $0.86, with InvestingPro analysis indicating the company is currently undervalued.
Following the transaction, Parker directly owns 1,276,796 shares of Allogene Therapeutics. This number includes 6,000 shares acquired on March 14, 2025, and another 6,000 shares acquired on September 15, 2025, through an employee stock purchase program. The company maintains strong liquidity with a current ratio of 8.92, though InvestingPro data shows rapid cash burn and weak profit margins.
The sale was mandated by Allogene Therapeutics’ equity incentive plan to cover tax withholding obligations related to the vesting of restricted stock units. The transaction does not represent a discretionary trade by Parker. Get access to 7 more exclusive InvestingPro Tips and comprehensive analysis through the Pro Research Report, available on InvestingPro.
In other recent news, Allogene Therapeutics reported its second-quarter 2025 earnings with a net loss of $50.9 million, or $0.23 per share, which was better than the anticipated loss of $0.2685 per share. The company also shared updates on strategic shifts within its clinical pipeline during the earnings call. In related developments, JPMorgan downgraded Allogene from Neutral to Underweight, citing concerns over the company’s near-term outlook and recent program changes. Analysts from JPMorgan expressed doubts about potential short-term growth catalysts for Allogene. Meanwhile, Citizens JMP maintained a Market Perform rating for Allogene, following the company’s earnings report. The firm noted that Allogene reaffirmed the timeline for its ALPHA3 futility analysis, set for the first half of 2026. These recent developments indicate ongoing scrutiny and mixed analyst sentiments regarding Allogene’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.